Drug Trial Radar · NCT05650320
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Feb 17, 2023
Primary completion
Jul 21, 2024
Study completion Jan 15, 2025
Sponsor
- Lead sponsor
- Otsuka Beijing Research InstituteOtsuka
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD. This trial consists of the 0.3% OPA-15406 group, the 1% OPA-15406 group, and the vehicle group.
Conditions
- Atopic Dermatitis (AD)
Interventions
0.3% OPA-15406 OintmentDrug
Twice-daily administration for 4 weeks.
1% OPA-15406 OintmentDrug
Twice-daily administration for 4 weeks.
0% OPA-15406 vehicleOther
Twice-daily administration for 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success rate in Investigator's Global Assessment at Week 4Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.